Marker Therapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 22, 2023. Marker is a clinical-stage immuno-oncology company developing non-engineered, multi-antigen-specific T-cell therapies. It had no approved products and generated no revenue from product sales or licensing.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Total revenue | $9.0 million | $1.2 million |
| Research and development | $26.1 million | $27.8 million |
| General and administrative | $12.8 million | $12.9 million |
| Operating loss | $(29.9) million | $(39.5) million |
| Net loss | $(29.9) million | $(41.9) million |
| Net loss per share | $(3.58) | $(5.47) |
| Cash, cash equivalents and restricted cash at year-end | $11.8 million | $43.5 million |
| Working capital at year-end | $8.8 million | $33.1 million |
| Cash used in operating activities | $27.0 million | $27.3 million |
- 2022 revenue comprised $3.5 million of grant income and $5.5 million of related-party service revenue from Wilson Wolf; it was not product revenue. The Wilson Wolf agreement provided $8.0 million upfront, of which $2.5 million remained deferred at year-end.
- Operating expenses declined 4%; net loss narrowed 29%, reflecting higher grant and service revenue, lower R&D expenses, and reduced arbitration expense versus 2021. Operating and net margins are not meaningful indicators for this pre-commercial company.
- Investing activities used $4.9 million, mainly for laboratory equipment and manufacturing-facility buildout. Financing activities provided only $0.2 million in 2022, compared with $52.6 million in 2021 from an underwritten offering.
- Year-end liabilities included $7.6 million of operating lease liabilities; the filing reports no material off-balance-sheet arrangements. The company’s cash runway estimate was into Q3 2023, and management and the auditor stated that substantial doubt existed about the company’s ability to continue as a going concern.
Material developments and outlook
- MT-401 for post-transplant AML: The Phase 2 ARTEMIS trial continued. Eleven patients had been randomized in the adjuvant arm, with outcomes too early to evaluate. Marker reported no objective responses among 15 treated frank-relapse patients and suspended further enrollment of that cohort while considering modifications. It anticipated reporting data for the MRD-positive subset in the second half of 2023.
- Marker reported a nine-day manufacturing process, compared with more than 30 days previously, and claimed improved specificity and fourfold in-vitro potency. These are company-reported process and laboratory findings, not established clinical benefit.
- Other programs: MT-401-OTS was in development, with first-patient dosing expected in 2023. FDA cleared MT-601’s IND for pancreatic cancer in November 2022; Marker expected to initiate the approximately 40-patient PANACEA Phase 1 study by Q4 2023. The MT-601 lymphoma Phase 1 APOLLO study began in Q1 2023, with a readout anticipated in Q1 2024.
- Marker received a $13.1 million CPRIT award for MT-401 and a $2.0 million FDA orphan-products grant. It recognized $3.4 million and $0.1 million, respectively, as 2022 grant income. CPRIT had disbursed $4.8 million through the filing date.
- In August 2022, Marker reduced general and administrative headcount by approximately 23.5%, including separating its CFO. It terminated its Mayo license agreements for peptide-vaccine programs in October 2022.
- In December 2022, Marker entered a 24-month agreement giving it the option to sell up to $25 million of stock to Lincoln Park; no shares had been sold under it by year-end. It also had an ATM facility, under which it sold approximately $0.2 million of stock in 2022. These financing options may dilute existing holders and do not assure funding.
- A FINRA arbitration award relating to prior financings was upheld. Marker paid approximately $2.5 million in March 2022 and recorded an additional approximately $0.1 million award in 2022, paid in January 2023.
- Subsequent events disclosed included the Chief Medical Officer’s planned April 2023 departure and a $0.4 million process-improvement agreement with AlloVir. The January 2023 one-for-ten reverse split is reflected retrospectively in reported share data.
Key risks and investor verification points
- Funding and dilution: Verify the latest cash balance, actual burn rate, grant receipts, and financing after the filing date. The stated runway was only into Q3 2023, and continuation depended on raising capital; equity issuance could materially dilute shareholders.
- Clinical evidence: Review trial registry updates and subsequent data, especially ARTEMIS’s randomized adjuvant arm and the MRD-positive subgroup. The filing reports no objective responses in the treated frank-relapse cohort and preliminary results from small studies do not establish efficacy.
- Manufacturing comparability: Verify regulatory acceptance and clinical performance of the improved nine-day process; the filing notes that manufacturing changes can affect product characteristics and may require additional testing.
- Related-party arrangement: Examine the Wilson Wolf agreement, including the services supporting $5.5 million of recognized revenue, the remaining $2.5 million deferred revenue, ownership of work-related intellectual property, and the facility rights and financing provisions described in the agreement.
- Governance and financing capacity: Review the Lincoln Park facility’s terms, the commitment-fee shares issued in January 2023, outstanding warrants and options, and the consequences of the reverse split for trading liquidity and Nasdaq listing.
- Going concern and controls: The auditor issued an unmodified financial-statement opinion but included a going-concern explanatory paragraph. Management reported effective disclosure controls and internal control over financial reporting; the auditor was not engaged to audit internal controls.